Advertisement
Advertisement
U.S. Markets open in 2 hrs 42 mins
Advertisement
Advertisement
Advertisement
Advertisement

Pulmatrix, Inc. (PULM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.9789+0.1139 (+2.95%)
At close: 04:00PM EDT
3.9100 -0.07 (-1.73%)
After hours: 07:16PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.8650
Open3.8500
Bid0.0000 x 1800
Ask3.9900 x 1000
Day's Range3.8050 - 4.0000
52 Week Range3.4000 - 20.8000
Volume52,497
Avg. Volume132,587
Market Cap223.81M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.6720
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • PR Newswire

    Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine (DHE) in healthy volunteers. Phase 1 data from this study is expected in Q4 2022.

  • PR Newswire

    Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced second quarter financial results for 2022 and provided a corporate update related to its development programs.

  • PR Newswire

    Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

    Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the dosing of the first five subjects in a Phase 1 trial evaluating PUR3100, a novel pulmonary inhaled formulation of dihydroergotamine (DHE). PUR3100 is formulated using Pulmatrix's iSPERSE drug delivery technology and is being developed for the treatment of acute migraine.

Advertisement
Advertisement